LYVE1 Human

Lymphatic Vessel Endothelial Hyaluronic Acid Receptor 1 Human Recombinant

Recombinant Human LYVE1, fused with a C-terminal His-tag (6xHis), is produced in a baculovirus expression system. It is a monomeric, glycosylated polypeptide with 232 amino acids (Met-1 to Gly 232). Although its molecular weight based on amino acid sequence is 25 kDa, glycosylation increases it to 40 kDa. The protein is purified using proprietary chromatographic techniques and supplied in a soluble form.
Shipped with Ice Packs
Cat. No.
BT7428
Source
Insect Cells.
Appearance
White, lyophilized (freeze-dried) powder, sterile filtered.

LYVE1 Human 25-235 a.a.

Lymphatic Vessel Endothelial Hyaluronic Acid Receptor 1 (25-235 a.a) Human Recombinant

Recombinant human LYVE1, spanning amino acids 25 to 235, has been expressed in insect cells and purified to yield a single, glycosylated polypeptide chain. This protein has a molecular weight of 24.8 kDa. Due to glycosylation, LYVE1 migrates at an apparent molecular weight of approximately 50 kDa on SDS-PAGE.

For purification purposes, LYVE1 has been engineered with a 15 amino acid His tag at its C-terminus and purified using proprietary chromatographic methods.

Shipped with Ice Packs
Cat. No.
BT7511
Source
High Five insect cells.
Appearance
A clear, colorless solution that has been sterilized by filtration.

LYVE1 Mouse Sf9

Lymphatic Vessel Endothelial Hyaluronic Acid Receptor 1 Mouse Recombinant, Sf9

Recombinant soluble LYVE1 from mouse, fused with a C-terminal His-tag (6xHis), is produced in baculovirus. This monomeric glycoprotein has a molecular weight of 25 kDa based on its 228 amino acid sequence (Met-1 to Gly 228). However, due to glycosylation, the apparent molecular weight is 40 kDa. The purification of LYVE-1 is achieved through proprietary chromatographic methods.
Shipped with Ice Packs
Cat. No.
BT7577
Source
Insect Cells.
Appearance
White, lyophilized powder, sterile filtered.
Definition and Classification

Lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1), also known as extracellular link domain containing 1 (XLKD1), is a type I integral membrane glycoprotein. It is a member of the hyaladherin family, which includes proteins capable of binding to hyaluronic acid (HA). LYVE1 is homologous to CD44, the primary HA receptor .

Biological Properties

Key Biological Properties: LYVE1 acts as a receptor that binds to both soluble and immobilized hyaluronan. It plays a role in lymphatic hyaluronan transport and may be involved in tumor metastasis .

Expression Patterns and Tissue Distribution: LYVE1 is primarily expressed on the surface of lymphatic endothelial cells. It is also found in normal liver blood sinusoids, embryonic blood vessels, and a subset of macrophages . Additionally, LYVE1 expression is observed in the meninges of rats, where LYVE1-positive macrophages are both lymphatic and alymphatic .

Biological Functions

Primary Biological Functions: LYVE1 is involved in the transport and turnover of hyaluronan. It promotes the localization of HA to the surfaces of lymphatic endothelium, which may facilitate cell migration, tissue morphogenesis, inflammation, and tumor metastasis .

Role in Immune Responses and Pathogen Recognition: LYVE1 plays a role in the immune response by providing a substrate for transmigrating CD44+ leukocytes or tumor cells. It is also involved in the internalization and degradation of HA, which can affect aspects of the immune response .

Modes of Action

Mechanisms with Other Molecules and Cells: LYVE1 interacts with hyaluronan on the plasma membrane and facilitates its transport to the lumen of lymphatic vessels. It also supports cellular HA internalization in vitro .

Binding Partners and Downstream Signaling Cascades: LYVE1 binds to hyaluronan and may interact with other molecules involved in the immune response and tumor metastasis. The exact downstream signaling cascades are still being studied .

Regulatory Mechanisms

Regulatory Mechanisms Controlling Expression and Activity: The expression of LYVE1 is regulated at the transcriptional level and may involve various transcription factors. Post-translational modifications, such as glycosylation, can also affect LYVE1 activity .

Transcriptional Regulation and Post-Translational Modifications: LYVE1 expression is controlled by specific transcription factors that bind to its promoter region. Post-translational modifications, including glycosylation, can influence its binding affinity and receptor activity .

Applications

Biomedical Research: LYVE1 is used as a marker for lymphatic endothelial cells, allowing for the isolation and study of these cells in various experimental settings .

Diagnostic Tools: LYVE1 antibodies are utilized in diagnostic applications, including immunohistochemistry and flow cytometry, to identify lymphatic endothelial cells and study lymphangiogenesis .

Therapeutic Strategies: Targeting LYVE1 and its interactions with hyaluronan may offer therapeutic potential in treating diseases related to lymphatic dysfunction, inflammation, and cancer metastasis .

Role in the Life Cycle

Role Throughout the Life Cycle: LYVE1 plays a crucial role in lymphatic vessel development, immune response, and tissue homeostasis from development to aging. Its expression in various tissues, including the liver, embryonic blood vessels, and macrophages, suggests its involvement in maintaining tissue integrity and function throughout life .

From Development to Aging and Disease: During development, LYVE1 is involved in the formation of lymphatic vessels and the regulation of tissue fluid homeostasis. In aging and disease, LYVE1 expression can be altered, contributing to conditions such as chronic inflammation and cancer metastasis .

© Copyright 2024 Thebiotek. All Rights Reserved.